sur Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Announces Nasdaq Listing Following Merger
Aspire Biopharma Holdings, Inc. has completed its business combination with PowerUp Acquisition Corp., establishing a presence on the Nasdaq under the ticker "ASBP" starting February 20, 2025. This move aims to enhance Aspire’s access to capital and foster expansion of its innovative product pipeline, which addresses key medical needs. The company is focused on breakthrough drugs like a fast-acting aspirin for cardiac emergencies and a novel Viagra/Cialis combo. Aspire leverages its unique sublingual delivery system for rapid absorption, bypassing the gastrointestinal tract.
Funds from the merger, totaling around $3.8 million, are set to advance Aspire's strategic growth, enable new partnerships, and drive trials for its leading aspirin product, a candidate for FDA fast-track approval. Leadership remains stable with Kraig Higginson as CEO, continuing to steer the company towards significant developments in biopharma technology.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Aspire Biopharma, Inc.